Stockreport

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical Holding Corporation  (ICU) 
PDF Data show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending to 90 days DENVER, [Read more]